Neuren Pharmaceuticals (ASX:NEU): How Did DAYBUE Sales Change Its 2026 Outlook?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Neuren Pharmaceuticals (ASX:NEU): How Did DAYBUE Sales Change Its 2026 Outlook?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Neuren Pharmaceuticals (ASX:NEU) raised trofinetide income guidance for 2026.
DAYBUE third-quarter net sales reached USD 140 million, up 39%.
Neuren earned USD 16.4 million in third-quarter Royalty income.
Germany’s DAYBU launch triggered a USD 35 million milestone.

Neuren Pharmaceuticals Limited (ASX:NEU) develops treatments for neurological disorders associated with genetic abnormalities or brain injury. On 12 November 2026, Neuren (ASX:NEU) shares stood at AUD 23.75, down 0.88% during the trading session. Its November update highlighted higher sales of licensed Rett syndrome treatment DAYBUE, an initial European commercial milestone and continuing development of the investigational compound NNZ-2591.

Licensed Therapy and Research Pipeline

Neuren (ASX:NEU) receives royalty and milestone income linked to trofinetide, commercialised by partner Acadia Pharmaceuticals under the DAYBUE Brand in the United States and other approved markets. The company’s wholly owned investigational asset NNZ-2591, also called ercanetide, is being studied in several neurodevelopmental conditions. Its commercial and clinical programmes have distinct risk profiles: approved-product royalties depend on partner sales, while research programmes depend on clinical and regulatory outcomes.

DAYBUE oral solution and the DAYBUE STIX powder formulation have US approval for Rett syndrome. The company reported that the oral solution has also received approvals in other jurisdictions. By contrast, NNZ-2591 remains investigational and is not an approved medicine. Neuren’s Koala Phase 3 study is evaluating NNZ-2591 in children with Phelan-McDermid syndrome, including a longer open-label extension.

November DAYBUE Sales and European Milestone

In its early-November announcement, Neuren (ASX:NEU) reported third-quarter 2026 DAYBUE net sales of USD 140 million by Acadia, 39% higher than the corresponding quarter and 12% higher than Q2 2026. Neuren’s earned third-quarter royalties were USD 16.4 million, an increase of 51% year on year. These sales belong to its commercial partner; Neuren recognises contractual royalty and milestone income rather than reporting Acadia’s entire DAYBUE turnover as its own revenue.

The launch of DAYBU in Germany during October 2026 generated a USD 35 million first-commercial-sale milestone for Neuren. Acadia also raised its 2026 global DAYBUE sales forecast to USD 505–520 million, compared with its previous USD 480–510 million range. Neuren reported more than half of US DAYBUE users were already using STIX, compared with 40% at the second-quarter end.

Financial Position and Revised Guidance

Neuren (ASX:NEU) increased its calendar-2026 expected total income from trofinetide, including royalties and milestones, to USD 91–93 million from USD 53–56 million. Within that expectation, royalty income was upgraded to USD 56–58 million from USD 53–56 million; the USD 35 million German milestone accounts for the principal difference between royalties and total trofinetide income. The outlook is conditional on commercial performance and is not a reported full-year result.

For the half-year ended June 2026, the company reported Revenue from ordinary activities of AUD 42.746 million and profit attributable to owners of AUD 4.852 million. Cash and short-term investments were approximately AUD 287 million at 30 June 2026. In August Neuren declared its first fully franked Interim Dividend of AUD 0.15 per share, reflecting a newly established dividend programme.

Clinical and Regulatory Risks

For Neuren (ASX:NEU), NNZ-2591 clinical studies can encounter enrolment delays, safety findings or outcomes that do not satisfy regulatory requirements. Rare-disease development also raises challenges involving trial endpoints and small patient populations. Trofinetide royalties remain sensitive to partner sales performance, product adoption, market access, patents and foreign-exchange translation. Regulatory designations do not establish treatment effectiveness or guarantee approval.

What to Watch Next

Neuren (ASX:NEU) has identified a potential Japanese regulatory submission for trofinetide in 2027, following trial results described as supportive; any commercial launch remains subject to approval. Investors can monitor further DAYBUE sales, German uptake and progress in the Koala trial. In November, Neuren also announced a planned board-chair succession, a governance development separate from its clinical programmes.

Key Insights

Neuren (ASX:NEU) reported rising DAYBUE royalties and a milestone payment arising from its German launch. Its upgraded 2026 income guidance captures those commercial developments. Continued clinical evaluation of NNZ-2591 and the separation between partner net sales and Neuren royalty income remain central to interpreting future updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.